Upstream Bio Advances Phase 3 Plans for Verekitug in Severe Asthma and CRSwNP
Event summary
- Upstream Bio plans to initiate Phase 3 trials for verekitug in severe asthma and CRSwNP in Q1 2027, following End-of-Phase 2 meetings with the FDA in mid-2026.
- The Phase 2 VENTURE trial in COPD has enrolled over 400 participants, with data expected in the second half of 2027.
- Upstream Bio reported $294.6 million in cash and short-term investments as of March 31, 2026, expected to fund operations through 2027.
- The company presented additional analyses of Phase 2 VIBRANT data at ATS and EAACI conferences.
The big picture
Upstream Bio is positioning verekitug as a potential best-in-class treatment for severe respiratory disorders, with a focus on delivering high efficacy with quarterly dosing convenience. The company's strategic shift to cap further enrollment in the Phase 2 VENTURE trial in COPD reflects its commitment to optimizing the efficacy profile across all indications. The biotech sector continues to prioritize innovative treatments for inflammatory diseases, and Upstream Bio's progress in clinical development could position it as a key player in this space.
What we're watching
- Regulatory Alignment
- Whether the FDA meetings in mid-2026 will align on Phase 3 plans for verekitug in severe asthma and CRSwNP.
- Clinical Efficacy
- The impact of the Phase 2 VENTURE trial data in COPD, expected in the second half of 2027, on the potential Phase 3 trial design.
- Financial Runway
- The pace at which Upstream Bio will need to secure additional funding beyond 2027, given its current cash position.
Related topics